Acknowledgement
Supported by : National Research Foundation of Korea
References
- Ali M, Nelson AR, Lopez AL, Sack DA. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis 2015;9:e0003832. https://doi.org/10.1371/journal.pntd.0003832
- Clemens JD, Nair GB, Ahmed T, Qadri F, Holmgren J. Cholera. Lancet 2017;390:1539-49. https://doi.org/10.1016/S0140-6736(17)30559-7
- Deen J, von Seidlein L, Luquero FJ, et al. The scenario approach for countries considering the addition of oral cholera vaccination in cholera preparedness and control plans. Lancet Infect Dis 2016;16:125-9. https://doi.org/10.1016/S1473-3099(15)00298-4
- Baker JP. Mercury, vaccines, and autism: one controversy, three histories. Am J Public Health 2008;98:244-53. https://doi.org/10.2105/AJPH.2007.113159
- Geier MR, Geier DA. Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication. Exp Biol Med (Maywood) 2003;228:660-4. https://doi.org/10.1177/153537020322800603
- Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics 2004;114: 793-804. https://doi.org/10.1542/peds.2004-0434
- Ball LK, Ball R, Pratt RD. An assessment of thimerosal use in childhood vaccines. Pediatrics 2001;107:1147-54. https://doi.org/10.1542/peds.107.5.1147
- World Health Organization. Guidelines on regulatory expectations related to the elimination, reduction or replacement of thiomersal in vaccines. WHO Technical Report Series, No. 926. Annex 4. Geneva: World Health Organization; 2004.
- World Health Organization. Vaccines and biologicals: recommendations from the strategic advisory group of experts, weekly epidemiologic record. WHO Weekly Epidemiological Record. Vol. 37. Geneva: World Health Organization; 2002.
- Kang SS, Yang JS, Kim KW, et al. Anti-bacterial and anti-toxic immunity induced by a killed whole-cell-cholera toxin B subunit cholera vaccine is essential for protection against lethal bacterial infection in mouse pulmonary cholera model. Mucosal Immunol 2013;6:826-37. https://doi.org/10.1038/mi.2012.121
- Yang JS, Kang SS, Yun CH, Han SH. Evaluation of anticoagulants for serologic assays of cholera vaccination. Clin Vaccine Immunol 2014;21:854-8. https://doi.org/10.1128/CVI.00012-14
- Yang JS, Kim HJ, Yun CH, et al. A semi-automated vibriocidal assay for improved measurement of cholera vaccine-induced immune responses. J Microbiol Methods 2007; 71:141-6. https://doi.org/10.1016/j.mimet.2007.08.009
- Clemens JD, Stanton BF, Chakraborty J, et al. B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity. J Infect Dis 1987;155:79-85. https://doi.org/10.1093/infdis/155.1.79
- Clemens JD, van Loon F, Sack DA, et al. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J Infect Dis 1991;163:1235-42. https://doi.org/10.1093/infdis/163.6.1235
- Mosley WH, Ahmad S, Benenson AS, Ahmed A. The relationship of vibriocidal antibody titre to susceptibility to cholera in family contacts of cholera patients. Bull World Health Organ 1968;38:777-85.
- Nygren E, Li BL, Holmgren J, Attridge SR. Establishment of an adult mouse model for direct evaluation of the efficacy of vaccines against Vibrio cholerae. Infect Immun 2009;77:3475-84. https://doi.org/10.1128/IAI.01197-08
- Villeneuve S, Boutonnier A, Mulard LA, Fournier JM. Immunochemical characterization of an Ogawa-Inaba common antigenic determinant of Vibrio cholerae O1. Microbiology 1999;145(Pt 9):2477-84. https://doi.org/10.1099/00221287-145-9-2477
- Baik YO, Choi SK, Olveda RM, et al. A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines. Vaccine 2015;33:6360-5. https://doi.org/10.1016/j.vaccine.2015.08.075
- Saha A, Chowdhury MI, Khanam F, et al. Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine 2011; 29:8285-92. https://doi.org/10.1016/j.vaccine.2011.08.108
- Holmgren J, Svennerholm AM. Bacterial enteric infections and vaccine development. Gastroenterol Clin North Am 1992;21:283-302.
- Qadri F, Ryan ET, Faruque AS, et al. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibody-secreting cell responses and other immunological markers. Infect Immun 2003;71:4808-14. https://doi.org/10.1128/IAI.71.8.4808-4814.2003
- Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis 1995;171:1387-98. https://doi.org/10.1093/infdis/171.6.1387
- Aktar A, Rahman MA, Afrin S, et al. Plasma and memory B cell responses targeting O-specific polysaccharide (OSP) are associated with protection against Vibrio cholerae O1 infection among household contacts of cholera patients in Bangladesh. PLoS Negl Trop Dis 2018;12:e0006399. https://doi.org/10.1371/journal.pntd.0006399
- Nandy RK, Albert MJ, Ghose AC. Serum antibacterial and antitoxin responses in clinical cholera caused by Vibrio cholerae O139 Bengal and evaluation of their importance in protection. Vaccine 1996;14:1137-42. https://doi.org/10.1016/0264-410X(96)00035-7
- Klose KE. The suckling mouse model of cholera. Trends Microbiol 2000;8:189-91. https://doi.org/10.1016/S0966-842X(00)01721-2
- Butterton JR, Ryan ET, Shahin RA, Calderwood SB. Development of a germfree mouse model of Vibrio cholerae infection. Infect Immun 1996;64:4373-7.
- Russo P, Ligsay AD, Olveda R, et al. A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol(R), a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines. Vaccine 2018;36:4317-24. https://doi.org/10.1016/j.vaccine.2018.05.102
Cited by
- Combating Cholera vol.8, pp.None, 2018, https://doi.org/10.12688/f1000research.18093.1
- Immunogenicity and protective efficacy of a live, oral cholera vaccine formulation stored outside-the-cold-chain for 140 days vol.21, pp.None, 2018, https://doi.org/10.1186/s12865-020-00360-1